The estimated Net Worth of Acquisition Corp Eli Lilly ... is at least 2.25 千$ dollars as of 22 January 2021. Acquisition Lilly owns over 34,284,789 units of Prevail Therapeutics Inc stock worth over 2,246$ and over the last 4 years Acquisition sold PRVL stock worth over 0$.
Sign up
Acquisition Lilly PRVL stock SEC Form 4 insiders trading
Acquisition has made over 1 trades of the Prevail Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Acquisition bought 34,284,789 units of PRVL stock worth 771,407,753$ on 22 January 2021.
The largest trade Acquisition's ever made was buying 34,284,789 units of Prevail Therapeutics Inc stock on 22 January 2021 worth over 771,407,753$. On average, Acquisition trades about 34,284,789 units every 0 days since 2021. As of 22 January 2021 Acquisition still owns at least 100 units of Prevail Therapeutics Inc stock.
You can see the complete history of Acquisition Lilly stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Acquisition Lilly's mailing address?
Acquisition's mailing address filed with the SEC is LILLY CORPORATE CENTERLILLY CORPORATE CENTER, , INDIANAPOLISINDIANAPOLIS, ININ, 4628546285.
Insiders trading at Prevail Therapeutics Inc
Over the last 5 years, insiders at Prevail Therapeutics Inc have traded over 0$ worth of Prevail Therapeutics Inc stock and bought 36,931,845 units worth 816,407,705$ . The most active insiders traders include Acquisition Corp Eli Lilly ...、Peter A. Thompson、Advisors Llc Orbi Med Capit.... On average, Prevail Therapeutics Inc executives and independent directors trade stock every 96 days with the average trade being worth of 138,767,762$. The most recent stock trade was executed by Acquisition Corp Eli Lilly ... on 22 January 2021, trading 34,284,789 units of PRVL stock currently worth 771,407,753$.
What does Prevail Therapeutics Inc's logo look like?
Complete history of Acquisition Lilly stock trades at Prevail Therapeutics Inc
Prevail Therapeutics Inc executives and stock owners
Prevail Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Asa Abeliovich,
President, Chief Executive Officer, Director -
Jeffrey Sevigny,
Chief Medical Officer -
Yong Dai,
Chief Technology Officer -
Franz Hefti,
Chief Development Officer -
Francois Nader,
Independent Chairman of the Board -
Timothy Adams,
Independent Director -
Morgan Sheng,
Independent Director -
Ran Nussbaum,
Independent Director -
Carl Gordon,
Director -
Peter Thompson,
Independent Director -
William Carson,
Director -
Emily Minkow,
Chief Business Officer -
Kira Schwartz,
General Counsel -
Brett Kaplan,
Chief Financial Officer -
Advisors Llc Orbi Med Capit...,
-
Acquisition Corp Eli Lilly ...,